Cellectar Biosciences, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Pre-funded warrants Common Stock	Pre-funded warrants Additional Paid-In Capital	Pre-funded warrants	Preferred Stock Series E-2 Preferred Stock	Preferred Stock Series E-3 preferred stock	Preferred Stock Series E-4 preferred stock	Preferred Stock	Common Stock Series E-2 Preferred Stock	Common Stock Series E-3 preferred stock	Common Stock Series E-4 preferred stock	Common Stock	Additional Paid-In Capital Series E-2 Preferred Stock	Additional Paid-In Capital Series E-3 preferred stock	Additional Paid-In Capital Series E-4 preferred stock	Additional Paid-In Capital	Accumulated Deficit	Series D preferred stock	Series E-2 Preferred Stock	Series E-4 preferred stock	Total
Balance beginning at Dec. 31, 2022											$ 94				$ 168,143,557	$ (159,990,407)				$ 8,153,244
Balance beginning (in shares) at Dec. 31, 2022											9,385,272
Balance beginning Series D preferred stock at Dec. 31, 2022																	$ 1,382,023
Balance beginning Series D preferred stock (in shares) at Dec. 31, 2022																	111.11
Stock-based compensation															2,410,288					2,410,288
Exercise of warrants into common shares											$ 12				2,467,210					$ 2,467,222
Exercise of warrants into common shares (in shares)											1,197,622
Conversion of preferred stock to common stock							$ (13,142,368)				$ 99				13,142,269
Conversion of preferred stock to common stock (in shares)							(905.24)				9,947,684
Reclassification of pre-funded warrants to liability liability		$ (3,239,112)	$ (3,239,112)
Stock awards											$ 2				(2)
Stock awards (in shares)											213,532									1,617,000
Fair value of the warrants allocated to preferred stock				$ 17,820,000														$ 17,820,000
Issuance of preferred stock, net of issuance costs (in shares)				1,225
Net loss																(42,770,610)				$ (42,770,610)
Balance ending Series D preferred stock at Dec. 31, 2023																	$ 1,382,023
Balance ending Series D preferred stock (in shares) at Dec. 31, 2023																	111.11
Balance ending at Dec. 31, 2023							$ 4,677,632				$ 207				182,924,210	(202,761,017)				(15,158,968)
Balance ending (in shares) at Dec. 31, 2023							319.76				20,744,110
Stock-based compensation															4,272,780					4,272,780
Exercise of warrants into common shares	$ 11	$ 3,972,529	$ 3,972,540								$ 5				2,298,138					2,298,143
Exercise of warrants into common shares (in shares)	1,079,132										547,177
Exercise of warrants for preferred stock, net of issuance costs							$ 47,577,000													$ 47,577,000
Exercise of warrants for preferred stock, net of issuance costs (in shares)							2,205
Conversion of preferred stock to common stock				$ (4,156,854)	$ (47,577,000)	$ (15,914,632)		$ 31	$ 139	$ 68		$ 4,156,823	$ 47,576,861	$ 15,914,564
Conversion of preferred stock to common stock (in shares)				(284)	(2,205)	(1,610)		3,122,637	13,846,141	6,739,919
Stock awards (in shares)																				3,063,500
Fair value of the warrants allocated to preferred stock						$ (15,914,632)													$ (15,914,632)
Issuance of preferred stock, net of issuance costs (in shares)						1,610
Stock option exercise into common stock (in shares)											767									1,667
Retired shares (in shares)											(8)
Net loss																(44,581,446)				$ (44,581,446)
Balance ending Series D preferred stock at Dec. 31, 2024																	$ 1,382,023
Balance ending Series D preferred stock (in shares) at Dec. 31, 2024																	111.11
Balance ending at Dec. 31, 2024							$ 520,778				$ 461				$ 261,115,905	$ (247,342,463)				$ 14,294,681
Balance ending (in shares) at Dec. 31, 2024							35.6				46,079,875